vs
Old Dominion（ODFL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Old Dominion的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Old Dominion净利率更高（17.9% vs 12.7%，领先5.1%），Revvity同比增速更快（5.9% vs -2.9%），过去两年Revvity的营收复合增速更高（9.0% vs -5.6%）
Old Dominion Freight Line（简称ODFL）是美国领先的零担货运企业，服务覆盖区域、跨区域及全国范围。除核心零担货运业务外，公司还提供加急运输、综合物流及家庭搬家服务，拥有成熟的运营网络，可满足不同客户的多元运输需求。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ODFL vs RVTY — 直观对比
营收规模更大
ODFL
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出8.8%
-2.9%
净利率更高
ODFL
高出5.1%
12.7%
两年增速更快
RVTY
近两年复合增速
-5.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $238.3M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 23.8% | 14.5% |
| 净利率 | 17.9% | 12.7% |
| 营收同比 | -2.9% | 5.9% |
| 净利润同比 | -6.4% | 3.9% |
| 每股收益（稀释后） | $1.14 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ODFLRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.5B | $691.7M |
净利润ODFLRVTY
| Q1 26 | $238.3M | — | ||
| Q4 25 | $229.5M | $98.4M | ||
| Q3 25 | $270.9M | $46.7M | ||
| Q2 25 | $268.6M | $53.9M | ||
| Q1 25 | $254.7M | $42.2M | ||
| Q4 24 | $263.1M | $94.6M | ||
| Q3 24 | $308.6M | $94.4M | ||
| Q2 24 | $322.0M | $55.4M |
毛利率ODFLRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ODFLRVTY
| Q1 26 | 23.8% | — | ||
| Q4 25 | 23.3% | 14.5% | ||
| Q3 25 | 25.7% | 11.7% | ||
| Q2 25 | 25.4% | 12.6% | ||
| Q1 25 | 24.6% | 10.9% | ||
| Q4 24 | 24.1% | 16.3% | ||
| Q3 24 | 27.3% | 14.3% | ||
| Q2 24 | 28.1% | 12.4% |
净利率ODFLRVTY
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.6% | 12.7% | ||
| Q3 25 | 19.3% | 6.7% | ||
| Q2 25 | 19.1% | 7.5% | ||
| Q1 25 | 18.5% | 6.4% | ||
| Q4 24 | 19.0% | 13.0% | ||
| Q3 24 | 21.0% | 13.8% | ||
| Q2 24 | 21.5% | 8.0% |
每股收益（稀释后）ODFLRVTY
| Q1 26 | $1.14 | — | ||
| Q4 25 | $1.10 | $0.86 | ||
| Q3 25 | $1.28 | $0.40 | ||
| Q2 25 | $1.27 | $0.46 | ||
| Q1 25 | $1.19 | $0.35 | ||
| Q4 24 | $1.23 | $0.77 | ||
| Q3 24 | $1.43 | $0.77 | ||
| Q2 24 | $1.48 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $288.1M | $919.9M |
| 总债务越低越好 | $40.0M | — |
| 股东权益账面价值 | $4.4B | $7.3B |
| 总资产 | $5.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资ODFLRVTY
| Q1 26 | $288.1M | — | ||
| Q4 25 | $120.1M | $919.9M | ||
| Q3 25 | $46.6M | $931.4M | ||
| Q2 25 | $24.1M | $991.8M | ||
| Q1 25 | $97.2M | $1.1B | ||
| Q4 24 | $108.7M | $1.2B | ||
| Q3 24 | $74.2M | $1.2B | ||
| Q2 24 | $104.6M | $2.0B |
总债务ODFLRVTY
| Q1 26 | $40.0M | — | ||
| Q4 25 | $20.0M | — | ||
| Q3 25 | $65.0M | — | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.0M | — |
股东权益ODFLRVTY
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.3B | $7.3B | ||
| Q3 25 | $4.3B | $7.4B | ||
| Q2 25 | $4.2B | $7.6B | ||
| Q1 25 | $4.2B | $7.6B | ||
| Q4 24 | $4.2B | $7.7B | ||
| Q3 24 | $4.2B | $7.9B | ||
| Q2 24 | $4.1B | $7.9B |
总资产ODFLRVTY
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.5B | $12.2B | ||
| Q3 25 | $5.5B | $12.1B | ||
| Q2 25 | $5.6B | $12.4B | ||
| Q1 25 | $5.5B | $12.4B | ||
| Q4 24 | $5.5B | $12.4B | ||
| Q3 24 | $5.4B | $12.8B | ||
| Q2 24 | $5.3B | $13.4B |
负债/权益比ODFLRVTY
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ODFLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $310.3M | $182.0M | ||
| Q3 25 | $437.5M | $138.5M | ||
| Q2 25 | $285.8M | $134.3M | ||
| Q1 25 | $336.5M | $128.2M | ||
| Q4 24 | $401.1M | $174.2M | ||
| Q3 24 | $446.5M | $147.9M | ||
| Q2 24 | $387.9M | $158.6M |
自由现金流ODFLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $264.5M | $161.8M | ||
| Q3 25 | $343.5M | $120.0M | ||
| Q2 25 | $98.7M | $115.5M | ||
| Q1 25 | $248.4M | $112.2M | ||
| Q4 24 | $230.1M | $149.8M | ||
| Q3 24 | $203.7M | $125.6M | ||
| Q2 24 | $149.7M | $136.6M |
自由现金流率ODFLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 20.2% | 21.0% | ||
| Q3 25 | 24.4% | 17.2% | ||
| Q2 25 | 7.0% | 16.0% | ||
| Q1 25 | 18.1% | 16.9% | ||
| Q4 24 | 16.6% | 20.5% | ||
| Q3 24 | 13.9% | 18.4% | ||
| Q2 24 | 10.0% | 19.7% |
资本支出强度ODFLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.5% | 2.6% | ||
| Q3 25 | 6.7% | 2.6% | ||
| Q2 25 | 13.3% | 2.6% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 12.3% | 3.4% | ||
| Q3 24 | 16.5% | 3.3% | ||
| Q2 24 | 15.9% | 3.2% |
现金转化率ODFLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 1.85× | ||
| Q3 25 | 1.61× | 2.97× | ||
| Q2 25 | 1.06× | 2.49× | ||
| Q1 25 | 1.32× | 3.03× | ||
| Q4 24 | 1.52× | 1.84× | ||
| Q3 24 | 1.45× | 1.57× | ||
| Q2 24 | 1.20× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ODFL
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
